menu
    • menu
    [{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"McGill University","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"2","companyTruncated":"McGill University \/ Clarus"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet, Film Coated","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals for Caspofungin

    Menu

    Caspofungin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Scynexis

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scynexis

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrexafungerp Citrate,Caspofungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : $401.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GSK Amends Deal with Scynexis Amid Brexafemme Manufacturing Woes

                            Details : GSK acquired the rights to develop and commercialize GSK5458448 (ibrexafungerp), a glucan synthase inhibitor, and market Brexafemme for antifungal indications outside China.

                            Brand Name : GSK5458448

                            Molecule Type : Small molecule

                            Upfront Cash : $90.0 million

                            January 03, 2024

                            Lead Product(s) : Ibrexafungerp Citrate,Caspofungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : $401.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Scynexis

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Scynexis

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrexafungerp Citrate,Caspofungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : $593.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement...

                            Details : Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive...

                            Brand Name : Brexafemme

                            Molecule Type : Small molecule

                            Upfront Cash : $90.0 million

                            June 21, 2023

                            Lead Product(s) : Ibrexafungerp Citrate,Caspofungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : $593.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            McGill University

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            McGill University

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10,Caspofungin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Clarus

                            Deal Size : $40.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Comm...

                            Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).

                            Brand Name : Ubiquinone

                            Molecule Type : Small molecule

                            Upfront Cash : $0.4 million

                            September 16, 2021

                            Lead Product(s) : Coenzyme Q10,Caspofungin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Clarus

                            Deal Size : $40.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth